HK1112627A1 - - Google Patents
Info
- Publication number
- HK1112627A1 HK1112627A1 HK08108251.9A HK08108251A HK1112627A1 HK 1112627 A1 HK1112627 A1 HK 1112627A1 HK 08108251 A HK08108251 A HK 08108251A HK 1112627 A1 HK1112627 A1 HK 1112627A1
- Authority
- HK
- Hong Kong
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004063864A DE102004063864A1 (de) | 2004-12-30 | 2004-12-30 | 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
| PCT/EP2005/014205 WO2006072467A1 (de) | 2004-12-30 | 2005-12-30 | 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische präparate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1112627A1 true HK1112627A1 (ru) | 2008-09-12 |
Family
ID=36087369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK08108251.9A HK1112627A1 (ru) | 2004-12-30 | 2008-07-25 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20090029953A1 (ru) |
| EP (1) | EP1831240B8 (ru) |
| JP (1) | JP5043681B2 (ru) |
| KR (1) | KR20070093443A (ru) |
| CN (1) | CN101128476B (ru) |
| AR (1) | AR052657A1 (ru) |
| AU (1) | AU2005324055A1 (ru) |
| BR (1) | BRPI0518533A2 (ru) |
| CA (1) | CA2594171C (ru) |
| CR (1) | CR9223A (ru) |
| CY (1) | CY1109498T1 (ru) |
| DE (2) | DE102004063864A1 (ru) |
| DK (1) | DK1831240T3 (ru) |
| EA (1) | EA014325B1 (ru) |
| ES (1) | ES2331322T3 (ru) |
| GT (1) | GT200500394A (ru) |
| HK (1) | HK1112627A1 (ru) |
| IL (1) | IL184288A (ru) |
| MX (1) | MX2007008074A (ru) |
| MY (1) | MY145904A (ru) |
| NO (1) | NO20073257L (ru) |
| NZ (1) | NZ556150A (ru) |
| PA (1) | PA8658401A1 (ru) |
| PE (2) | PE20060853A1 (ru) |
| PL (1) | PL1831240T3 (ru) |
| PT (1) | PT1831240E (ru) |
| RS (1) | RS51128B (ru) |
| SI (1) | SI1831240T1 (ru) |
| TW (1) | TW200635942A (ru) |
| UA (1) | UA90496C2 (ru) |
| UY (1) | UY29320A1 (ru) |
| WO (1) | WO2006072467A1 (ru) |
| ZA (1) | ZA200706254B (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006030416A1 (de) * | 2006-06-29 | 2008-01-03 | Bayer Schering Pharma Ag | 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate |
| DE102007027637A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007027635A1 (de) * | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007027636A1 (de) * | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007063495A1 (de) * | 2007-12-29 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel |
| DE102007063500A1 (de) | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | 17-(1'-Propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007063496A1 (de) * | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007063501A1 (de) * | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | 15, 16-Methylen-17-hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007063499A1 (de) * | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | Steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007063503A1 (de) * | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007063498A1 (de) * | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| WO2009111574A2 (en) * | 2008-03-05 | 2009-09-11 | Evestra, Inc. | BISMETHYLENE-17α CARBOLACTONES AND RELATED USES |
| DE102008026793A1 (de) | 2008-06-02 | 2009-12-03 | Bayer Schering Pharma Aktiengesellschaft | C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
| CN101623287B (zh) * | 2008-07-07 | 2012-02-08 | 天津金耀集团有限公司 | 一种屈螺酮类似物的治疗更年期综合症的药物组合物 |
| WO2010068500A2 (en) * | 2008-11-25 | 2010-06-17 | Evestra, Inc. | PROGESTATIONAL 3-(6,6-ETHYLENE-17b-HYDROXY-3-OXO-17a-PREGNA-4-ENE-17a -YL) PROPIONIC ACID g-LACTONES |
| WO2010066354A1 (de) * | 2008-12-12 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG |
| WO2010066349A1 (de) * | 2008-12-12 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von 17beta-cyano-19-androst-4-en-derivaten zur herstellung eines arzneimittels in depot-form zur parenteralen anwendung sowie depot-arzneimittel enthaltend 17beta-cyano-19-androst-4-en-derivate zur parenteralen anwendung |
| WO2010066355A1 (de) * | 2008-12-12 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG |
| WO2012059594A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959322A (en) * | 1960-09-22 | 1976-05-25 | Herchel Smith | Synthesis of 13-alkyl-gon-4-ones |
| DE3022337A1 (de) * | 1980-06-11 | 1982-01-07 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen |
| DE3402329A1 (de) * | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| FR2739029B1 (fr) * | 1995-09-21 | 1997-11-21 | Roussel Uclaf | Nouvelle application therapeutique des composes antimineralo-corticoides |
| DE19651000A1 (de) * | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
-
2004
- 2004-12-30 DE DE102004063864A patent/DE102004063864A1/de not_active Ceased
-
2005
- 2005-12-28 UY UY29320A patent/UY29320A1/es not_active Application Discontinuation
- 2005-12-28 AR ARP050105574A patent/AR052657A1/es unknown
- 2005-12-29 GT GT200500394A patent/GT200500394A/es unknown
- 2005-12-29 TW TW094147315A patent/TW200635942A/zh unknown
- 2005-12-29 PA PA20058658401A patent/PA8658401A1/es unknown
- 2005-12-29 MY MYPI20056249A patent/MY145904A/en unknown
- 2005-12-30 DE DE502005007723T patent/DE502005007723D1/de active Active
- 2005-12-30 US US11/813,251 patent/US20090029953A1/en not_active Abandoned
- 2005-12-30 SI SI200530803T patent/SI1831240T1/sl unknown
- 2005-12-30 AU AU2005324055A patent/AU2005324055A1/en not_active Abandoned
- 2005-12-30 EP EP05850392A patent/EP1831240B8/de active Active
- 2005-12-30 BR BRPI0518533-5A patent/BRPI0518533A2/pt not_active IP Right Cessation
- 2005-12-30 PT PT05850392T patent/PT1831240E/pt unknown
- 2005-12-30 JP JP2007548774A patent/JP5043681B2/ja not_active Expired - Fee Related
- 2005-12-30 WO PCT/EP2005/014205 patent/WO2006072467A1/de active Application Filing
- 2005-12-30 NZ NZ556150A patent/NZ556150A/en not_active IP Right Cessation
- 2005-12-30 ES ES05850392T patent/ES2331322T3/es active Active
- 2005-12-30 RS RSP-2009/0443A patent/RS51128B/sr unknown
- 2005-12-30 MX MX2007008074A patent/MX2007008074A/es active IP Right Grant
- 2005-12-30 CN CN2005800486803A patent/CN101128476B/zh not_active Expired - Fee Related
- 2005-12-30 EA EA200701239A patent/EA014325B1/ru not_active IP Right Cessation
- 2005-12-30 DK DK05850392T patent/DK1831240T3/da active
- 2005-12-30 KR KR1020077017382A patent/KR20070093443A/ko not_active Application Discontinuation
- 2005-12-30 PL PL05850392T patent/PL1831240T3/pl unknown
- 2005-12-30 UA UAA200708684A patent/UA90496C2/ru unknown
- 2005-12-30 CA CA2594171A patent/CA2594171C/en not_active Expired - Fee Related
-
2006
- 2006-01-03 PE PE2006000006A patent/PE20060853A1/es not_active Application Discontinuation
- 2006-01-03 PE PE2009001212A patent/PE20100736A1/es not_active Application Discontinuation
-
2007
- 2007-06-25 NO NO20073257A patent/NO20073257L/no not_active Application Discontinuation
- 2007-06-28 IL IL184288A patent/IL184288A/en not_active IP Right Cessation
- 2007-07-03 CR CR9223A patent/CR9223A/es not_active Application Discontinuation
- 2007-07-27 ZA ZA200706254A patent/ZA200706254B/xx unknown
-
2008
- 2008-07-25 HK HK08108251.9A patent/HK1112627A1/xx not_active IP Right Cessation
-
2009
- 2009-10-15 CY CY20091101073T patent/CY1109498T1/el unknown
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20141230 |